{"id":26462,"date":"2024-01-18T16:00:01","date_gmt":"2024-01-18T15:00:01","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=26462"},"modified":"2024-01-18T16:37:32","modified_gmt":"2024-01-18T15:37:32","slug":"camurus-has-carried-out-a-directed-share-issue-of-2000000-shares-at-a-subscription-price-of-sek-545-per-share-raising-gross-proceeds-of-sek-1090-million","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/en\/assignment\/camurus-has-carried-out-a-directed-share-issue-of-2000000-shares-at-a-subscription-price-of-sek-545-per-share-raising-gross-proceeds-of-sek-1090-million\/","title":{"rendered":"Camurus has carried out a directed share issue"},"content":{"rendered":"<p class=\"preamble\">The board of directors of Camurus has, based on an authorization to issue shares granted by the 2023 annual general meeting, resolved on a directed issue of 2,000,000 new shares at a subscription price of SEK 545 per share, consequently raising gross proceeds of SEK 1,090 million before deduction of transaction costs.<\/p>\n<p>The subscription price in the directed issue was determined through an accelerated book-building procedure directed to Swedish and international professional and institutional investors.<\/p>\n<p>Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company\u2019s proprietary FluidCrystal\u00ae drug delivery technologies and its extensive R&amp;D expertise. Camurus\u2019 clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disorders, developed in-house and in collaboration with international pharmaceutical companies. The company\u2019s shares are listed on Nasdaq Stockholm under the ticker CAMX.<\/p>\n<p>Camurus was advised by Mannheimer Swartling in connection with the share issue.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The board of directors of Camurus has, based on an authorization to issue shares granted by the 2023 annual general meeting, resolved on a directed\u2026<\/p>\n","protected":false},"author":16,"featured_media":26459,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4313],"tags":[],"class_list":["post-26462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-assignment","business-group-public-ma-and-equity-capital-markets"],"acf":[],"lang":"en","translations":{"en":26462,"sv":26457},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/26462"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=26462"}],"version-history":[{"count":4,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/26462\/revisions"}],"predecessor-version":[{"id":26468,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/26462\/revisions\/26468"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/26459"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=26462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=26462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=26462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}